COVID-19 |

Dr. Svetlana Kotliarova

Dr. Svetlana Kotliarova

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology – Translational Clinical OTC
Study Section:
Cancer Prevention Study Section CPSS

Dr. Svetlana Kotliarova received her M.S. in biochemistry and molecular biology from the Novosibirsk University in Russia. Her initial research was on the nucleotide excision repair. After receiving her Ph.D. in human genetics from the University of Tokyo, Japan, Dr. Kotliarova completed postdoctoral training under the Japanese Society for Promotion of Science Fellowship in the Department of Human Genetics of the University of Tokyo. During that time, she has identified several ethnic-specific loci on the Y chromosome. She then joined the RIKEN Brain Science Institute (BSI) as a staff scientist and studied neurodegenerative disorders. While at BSI, she developed a novel transgenic model for Huntington’s Disease (HD) and discovered the degeneration of hypothalamus in the HD mouse model. Before joining CSR, Dr. Kotliarova pursued brain tumor research in the Neuro-Oncology Branch of Howard Fine at the National Cancer Institute, where she was the head of the Genomics Core. Her research interests included glioma stem cells, gliomagenesis, genomics and development of new therapies for brain tumors. Dr. Kotliarova was the first to demonstrate a role of GSK3 in gliomas. Her research is published in Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry, Human Molecular Genetics, Scientific Reports, Cancer Cell and other journals.